L-CsA for Prevention of Bronchiolitis Obliterans Syndrome Following LT

• Research type

  Research Study

• Full title

  A phase II, multicentre, randomised, double-blind, placebo controlled, parallel group, dose-finding clinical trial to investigate the efficacy and safety of 10 and 20 mg/day aerosolised liposomal ciclosporin A (L-CsA) versus aerosolised placebo in the prevention of bronchiolitis obliterans syndrome (BOS) in lung transplant (LT) patients

• IRAS ID

  15267

• Sponsor organisation

  PARI Pharma GmbH

• Eudract number

  2008-003800-73

• ISRCTN Number

  66069132

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  N/A

• REC name

  East of England - Cambridge East Research Ethics Committee

• REC reference

  09/H0304/47

• Date of REC Opinion

  27 Aug 2009

• REC opinion

  Further Information Favourable Opinion